Browse by Industry
Filter News
Found 48,990 articles
-
Life is full of twists and turns, but there are always new opportunities around the corner, even when we hit the pause button on our careers. Getting back into the industry doesn’t have to be scary or overwhelming. You can have a successful job search if you take a step-by-step approach.
-
Here's a roundup of some of the top clinical trial news from the previous week.
-
New Study Evaluates Ability of Masimo SpHb® (Noninvasive Hemoglobin) to Estimate Timing for Invasive Measurement to Detect Anemia During Surgery
5/20/2019
Masimo announced the results of a study published in BMC Anesthesiology in which clinicians at Peking Union Medical College in Beijing evaluated the ability of noninvasive and continuous hemoglobin monitoring with Masimo SpHb® to help clincians estimate when to conduct invasive hemoglobin measurement to detect possible anemia in patients undergoing spine or cytoreductive surgery.
-
Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt Securities - May 20, 2019
5/20/2019
Becton, Dickinson and Company announced that it has commenced tender offers to purchase for cash the debt securities issued by the Company listed in the table below.
-
Saluda Medical Announces New 3-Month, 12-Month and 18-Month Data Featuring Evoke® ECAP-Controlled, Closed-Loop SCS System to be Presented at 14th INS World Congress
5/20/2019
11 Presentations - Including 4 Plenary Presentations - to Feature the Evoke System
-
New Exploratory Data from VARSITY, First Head-to-Head Ulcerative Colitis Biologic Study Which Demonstrated Superiority of Vedolizumab to Adalimumab in Clinical Remission at Week 52, Presented at 2019 Digestive Disease Week®
5/20/2019
Takeda Pharmaceutical Company Limited announced further results from the Phase 3b head-to-head VARSITY study, which demonstrated that the gut-selective biologic vedolizumab was superior to the anti-tumor necrosis factor-alpha biologic adalimumab in achieving clinical remission* at week 52 in patients with moderately to severely active ulcerative colitis.
-
A New Approach to Treating Alzheimer's Disease Receives Major NIA Backing
5/20/2019
T3D Therapeutics to Receive $9 Million Multiyear National Institute on Aging Grant for Phase 2 PIONEER Study in Mild-to-Moderate Alzheimer's Disease Patients
-
QIAGEN Gains 510(k) Clearance by FDA for QIAstat-Dx in the U.S. and Launches System as Next Generation Platform for Syndromic Insights
5/20/2019
Molecular diagnostic testing for accurate clinical insights on hard-to-diagnose syndromes, initial launch with respiratory panel for detection of more than 20 pathogens
-
Personalis, Inc. to Present at Advances in Immuno-Oncology Congress UK 2019
5/20/2019
Personalis, Inc., a leader in advanced genomics for cancer, announced that the company will present at Advances in Immuno-Oncology Congress UK 2019 in London on May 21st at 11:00 AM BST.
-
FSD Pharma Welcomes All-Star Lineup of Cannabis Researchers to Scientific Advisory Board
5/20/2019
Daniele Piomelli, Ph.D., Ryan Vandrey, Ph.D. and David Casarett, MD, MA Join distinguished group of Scientific Advisors
-
Lin Huang, chief executive officer of BeyondSpring, believes her company has the “secret sauce” that could provide beneficial treatment to chemotherapy-induced neutropenia, a common side effect for chemotherapy patients.
-
Promising Clinical Data from Pilot Study of Gelesis’ Novel Hydrogel GS500 Prototype for the Potential Treatment of Chronic Constipation Presented at Digestive Disease Week
5/19/2019
Gelesis announced the presentation of data from a clinical study demonstrating that GS500 prototype provided a significant reduction in colonic transit time in patients with chronic idiopathic constipation relative to placebo.
-
Schrödinger Announces Close of Latest Financing, Raising Total of $110 Million
5/19/2019
New funding to support platform advancements and proprietary pipeline expansion
-
The Aesthetic Surgery Education And Research Foundation Elects Robert Whitfield, MD As Its New President
5/19/2019
Mission to Include Breast Implant Illness Research and Funding for Data Collection and Standardization Technology
-
DDW 2019: New Study Shows SonarMD Lowers Cost of Managing Crohn’s Disease
5/19/2019
When people with Crohn’s disease worked together with their gastroenterologists to detect and address worsening symptoms sooner – using SonarMD’s care coordination solution – they were more likely to stay out of the hospital.
-
New York City Plastic Surgeon, Charles H. Thorne, MD, Named New President Of The Aesthetic Society
5/19/2019
New Board Members Elected at The Aesthetic Meeting 2019 in New Orleans
-
Age, Gender, Disease Severity Impact Adherence to Long-Term PAP Therapy More Than Previously Thought
5/19/2019
ResMed revealed several demographic and clinical factors affect adherence to PAP (positive airway pressure) therapy, according to a study it presented at the American Thoracic Society's ATS 2019 International Conference.
-
An Independent Data Monitoring Committee recommended the trial be stopped because of lack of survival benefit for patients receiving the drug compared to placebo.
-
Pfizer's Fragmin was approved to reduce the recurrence of VTE in patients one month of age or older.
-
Project Facilitate is a pilot project to create a single point of contact for the FDA’s oncology expanded access requests.